Wuhan Hvsen Biotechnology Stock Book Value Per Share
| 300871 Stock | 11.01 0.60 5.17% |
Wuhan Hvsen Biotechnology fundamentals help investors to digest information that contributes to Wuhan Hvsen's financial success or failures. It also enables traders to predict the movement of Wuhan Stock. The fundamental analysis module provides a way to measure Wuhan Hvsen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Wuhan Hvsen stock.
Wuhan | Book Value Per Share |
Wuhan Hvsen Biotechnology Company Book Value Per Share Analysis
Wuhan Hvsen's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Wuhan Hvsen Book Value Per Share | 8.62 X |
Most of Wuhan Hvsen's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Wuhan Hvsen Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Wuhan Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Wuhan Hvsen Biotechnology is about 8.622 times. This is 607.18% lower than that of the Biotechnology sector and 103.47% lower than that of the Health Care industry. The book value per share for all China stocks is 99.55% higher than that of the company.
Wuhan Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Wuhan Hvsen's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Wuhan Hvsen could also be used in its relative valuation, which is a method of valuing Wuhan Hvsen by comparing valuation metrics of similar companies.Wuhan Hvsen is currently under evaluation in book value per share category among its peers.
Wuhan Fundamentals
| Return On Equity | -0.0312 | ||||
| Return On Asset | -0.0029 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 2.39 B | ||||
| Shares Outstanding | 165.77 M | ||||
| Shares Owned By Insiders | 60.51 % | ||||
| Shares Owned By Institutions | 3.84 % | ||||
| Price To Book | 1.37 X | ||||
| Price To Sales | 1.64 X | ||||
| Revenue | 1.02 B | ||||
| Gross Profit | 222.75 M | ||||
| EBITDA | 150.08 M | ||||
| Net Income | 16.78 M | ||||
| Total Debt | 240.32 M | ||||
| Book Value Per Share | 8.62 X | ||||
| Cash Flow From Operations | 92.92 M | ||||
| Earnings Per Share | (0.28) X | ||||
| Target Price | 17.89 | ||||
| Number Of Employees | 1.07 K | ||||
| Beta | 0.47 | ||||
| Market Capitalization | 1.84 B | ||||
| Total Asset | 2.98 B | ||||
| Retained Earnings | 341.94 M | ||||
| Working Capital | 484.9 M | ||||
| Annual Yield | 0.02 % | ||||
| Net Asset | 2.98 B | ||||
| Last Dividend Paid | 0.27 |
About Wuhan Hvsen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Wuhan Hvsen Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Wuhan Hvsen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Wuhan Hvsen Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Wuhan Stock
Wuhan Hvsen financial ratios help investors to determine whether Wuhan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Wuhan with respect to the benefits of owning Wuhan Hvsen security.